Torisel 25mg/Ml Infusion
Temsirolimus (concentrate)
25mg/ml
Pfizer Europe MA EEIG
| Pack size | 1 Vial (1.2ml Concentrate) + 1 Diluent Vial (1.8ml) |
|---|---|
| Dispensing mode | POM |
| Source | BELGIUM |
| Agent | MODERN PHARMACEUTICAL COMPANY |
| Retail Price | 5458.50 AED |
Indications
Torisel 25mg/Ml Infusion is used for:
For the treatment of renal cell carcinoma (RCC). Also investigated for use/treatment in breast cancer, lymphoma (unspecified), rheumatoid arthritis, and multiple myeloma
Adult Dose
Child Dose
Renal Dose
Administration
Contra Indications
Precautions
Pregnancy-Lactation
Interactions
Adverse Effects
Side effects of Temsirolimus (concentrate) :
Mechanism of Action
Temsirolimus is an inhibitor of mTOR (mammalian target of rapamycin). Temsirolimus binds to an intracellular protein (FKBP-12), and the protein-drug complex inhibits the activity of mTOR that controls cell division. Inhibition of mTOR activity resulted in a G1 growth arrest in treated tumor cells. When mTOR was inhibited, its ability to phosphorylate p70S6k and S6 ribosomal protein, which are downstream of mTOR in the PI3 kinase/AKT pathway was blocked. In in vitro studies using renal cell carcinoma cell lines, temsirolimus inhibited the activity of mTOR and resulted in reduced levels of the hypoxia-inducible factors HIF-1 and HIF-2 alpha, and the vascular endothelial growth factor
Note
Torisel 25mg/Ml 25mg/ml Infusion manufactured by Pfizer Europe MA EEIG. Its generic name is Temsirolimus (concentrate). Torisel 25mg/Ml is availble in United Arab Emirates.
Farmaco UAE drug index information on Torisel 25mg/Ml Infusion is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.